NDAINJECTIONINJECTABLE
Approved
Aug 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 26m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Regonol (pyridostigmine bromide) is an injectable cholinesterase inhibitor used primarily in anesthesia to reverse neuromuscular blockade and in the management of myasthenia gravis. It works by inhibiting acetylcholinesterase, increasing acetylcholine availability at the neuromuscular junction. The drug has been a standard of care since 1973 for perioperative muscle relaxant reversal.
$0.042BPart D
LOE ApproachingProduct approaching end-of-life with minimal current commercial activity; limited opportunities for team growth or expansion roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Regonol offers limited career growth opportunities due to its LOE-approaching status, minimal linked job openings, and declining commercial footprint. Career development on this product is best suited for professionals seeking stability in a mature, commoditized market rather than leadership advancement or innovative project exposure.
Sales Representative (institutional/hospital-focused)
Worked on REGONOL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.